Macrophage Pharma Limited
Records under this name other than patents Macrophage Pharma Limited holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 7 of 7 · Back to Macrophage Pharma Limited
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,778,953 | Inhibitors of P38 Map Kinase Lapsed on the fee record Ended Jul 15, 2026 · High confidence | Lapsed on the fee record | Ended Jul 15, 2026 | High confidence |
| US 11,382,902 | Treatment of Cancer by Stimulation of IL-12 Production Lapsed on the fee record Ended Jul 12, 2026 · High confidence | Lapsed on the fee record | Ended Jul 12, 2026 | High confidence |
| US 9,896,417 | Tert-butyl N-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2H)-yl]-3,5-difluorophenyl}ethyl]-L-alaninate or a salt,hydrate or solvate thereof Lapsed on the fee record Ended Feb 20, 2026 · From the USPTO record | Lapsed on the fee record | Ended Feb 20, 2026 | From the USPTO record |
| US 9,388,136 | Tert-butyl N-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2H)-yl]-3,5-difluorophenyl}ethyl]-L-alaninate or a salt, hydrate or solvate thereof Lapsed on the fee record Ended Jul 12, 2024 · From the USPTO record | Lapsed on the fee record | Ended Jul 12, 2024 | From the USPTO record |
| US 8,044,211 | P38 MAP kinase inhibitors Lapsed on the fee record Ended Oct 25, 2023 · From the USPTO record | Lapsed on the fee record | Ended Oct 25, 2023 | From the USPTO record |
| US 10,370,332 | Tert-butyl N-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2H)-YL]-3,5-difluorophenyl}ethyl]-L-alaninate or a salt, hydrate or solvate thereof Lapsed on the fee record Ended Aug 6, 2023 · From the USPTO record | Lapsed on the fee record | Ended Aug 6, 2023 | From the USPTO record |
| US 9,604,940 | 2-aminopyrazine derivatives as CSF-1R kinase inhibitors Lapsed on the fee record Ended Mar 28, 2021 · From the USPTO record | Lapsed on the fee record | Ended Mar 28, 2021 | From the USPTO record |